India shifts to early-stage investments in biologics and genomics | Healthcare Asia Magazine
, India

India shifts to early-stage investments in biologics and genomics

Its exit market remained strong in the first half of 2023.

India has started to transition up its pharma value chain with early-stage investments in biologics and genomics, according to a Global Private Capital Association report.

The market, which is known as a leading supplier of generic medicines, is seen to grow its pharmaceuticals sector to US$130b by 2030.

Its healthcare exit market is also improving with a US$3.6b deal value in the first half of 2023.

“NIIF and TPG’s secondary sale of Manipal Health Enterprises to Temasek stands out as the largest healthcare exit on record in India,” read the report.

In addition to secondary sales, India’s robust public markets have also proven to be an active exit source, with IPOs and follow-on public-market transactions that accounted for 39% of India’s aggregate exit value since 2021.

Join Healthcare Asia Magazine community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!